Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Could be they found a way to monetize POLYSTART.
Because it isn’t worthy.
A virus changed the world and it could give POLYSTART a purpose. I am willing to consider it until shown otherwise.
A product is going to be manufactured and whatever it is the company owns it.
I disagree. AML is a small stalled trial and comes nowhere near explaining the space.
Both links are provided but did not format well.
The manufacturing facility press release is within two weeks of the POLYSTART trademark application.
https://uspto.report/TM/90050163
https://www.markertherapeutics.com/2020/06/marker-therapeutics-announces-new-manufacturing-facility-to-support-clinical-development-of-multitaa-specific-t-cell-therapy-product-candidates/
The manufacturing facility press release is within two weeks of the POLYSTART trademark application.
https://uspto.report/TM/90050163
https://www.markertherapeutics.com/2020/06/marker-therapeutics-announces-new-manufacturing-facility-to-support-clinical-development-of-multitaa-specific-t-cell-therapy-product-candidates/
The company press release said it was a manufacturing facility. When I was researching the USAN last month there was activity on the POLYSTART trademark. Those dots connect.
The ox is slow but the earth is patient.
Buckle up.
That space holds 200 to 300 employees depending on layout. GREX uses minimal manufacturing space. With their employee count 5,000 ft for offices is adequate. There is something else.
Information is scarce so I interpret the best I can. The next quarterly is close and either they provide insight or it will be more of the same.
It was the March 4th Cowen presentation. I do not believe specifics were given but distinctly remember $50,000. I also remember 30 employees which was considerably more than the previous number.
I neglected to include they priced the therapy. Revenue models are built off this along with an agreement such as licensing.
Production. Manufacturing facility is center to the press release. POLYSTART and Zelenoleucel are results of a branding initiative. Branding occurs when there is a product to sell. Here is a partial description of their Kite hire “Nadia Agopyan joined Marker in August 2019 from Kite Pharma, a subsidiary of Gilead Sciences, where she served as Director of Regulatory Affairs, Global Regulatory Lead. In this role, she was responsible for overseeing the global marketing authorization.” While the FDA delay has been in focus management took paths with less resistance. Space of that magnitude is not taken hoping for growth or a way to pay for it.
They are building a Brand.
“T-cells a great marker of immunity”
?https://news.yahoo.com/covid-breakthrough-oxford-university-says-011235872.html
I noticed the POLYSTART application while researching the USAN approval. I found this in my search.
“Because many more drugs enter clinical trials than are approved for market, many USAN are assigned to substances that are never sold in the U.S., but could be available in countries outside the U.S.”
A foreign entity licensing agreement? Every theory of mine to date has been wrong.
It was my intent to clarify timing. Fully operational does not mean space will not be utilized prior. One would hope revenues are driving this but the way management has conducted itself who can tell.
“FACILITY EXPECTED TO BE BUILT BY YEAR-END, FULLY OPERATIONAL IN 2021” is clearly stated in the press release. Transitioning early 2021 is a reasonable timeframe.